Pharmacia Ab

Pharmacia & Upjohn Ab

Kabi Pharmacia Ab

Martin Haraldsson

Erik Ringberg

Rolf A Johansson

Lars-Inge Olsson

Katarina Beierlein

Leif G Ahrgren

Birger Sjoberg

Thomas Berglindh

Hubert Agback

Eva ANGkerblom

Birgitta Weinz

Ian Vagberg

Goran Smedegard

Goran Smedegangrd

G Oran Smedegangrd

The invention relates to novel compounds of Formula (I) wherein R,, R,, R,, R,, R,, R,, R,and Ar are as defined in claim,their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary tract incontinence, and methods for preparing the compounds of Formula (I).

Therapeutically active diarylpropylamines; their pharmaceutically acceptable salts; a method for their preparation and method for their use

Arylcycloalkane carboxylic esters, their use, pharmaceutical

A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomic form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl. The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

N-heterocyclic substituted salicylic acids

Substituted salicylic acids

A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomeric form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl. The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

Compounds containing an amino salicylic acid moiety linked to a

Growing community of inventors

Vallentuna, Sweden

Martin Haraldsson